24C Stock Chart & Stats
€3.15
-€0.11(-3.37%)
At close: 4:00 PM EDT
€3.15
-€0.11(-3.37%)
Day’s Range― - ―
52-Week Range€2.18 - €3.38
Previous CloseN/A
Volume0.00
Average Volume (3M)162.00
Market Cap
€112.80M
Enterprise Value€1.10K
Total Cash (Recent Filing)€138.20M
Total Debt (Recent Filing)€9.10M
Price to Earnings (P/E)24.8
Beta0.38
Next Earnings
Oct 22, 2026EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.48
Shares Outstanding32,904,050
10 Day Avg. Volume200
30 Day Avg. Volume162
Financial Highlights & Ratios
PEG Ratio-1.27
Price to Book (P/B)3.12
Price to Sales (P/S)2.45
P/FCF Ratio21.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.14
Revenue Forecast (FY)€41.25M
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet / Low LeverageExtremely low leverage gives C‑Rad flexibility to fund R&D, absorb hospital capex cyclicality and support installs or service expansion without heavy interest burdens. This balance sheet strength lowers solvency risk and supports multi-year strategic investment plans.
Improved Operating ProfitabilityRecent margin improvement to healthy EBIT and positive net margins indicates the core business can generate sustainable operating profits. Stronger margins support reinvestment in software and aftermarket services and create a buffer against cost fluctuations.
Installed-base Model With Recurring RevenueCombination of hardware sales, software modules and recurring service/maintenance creates an installed‑base revenue engine. Attachments and service contracts raise switching costs and smooth revenue over time, enhancing long‑term earnings visibility and customer stickiness.
Bears Say
Uneven Revenue Growth And Recent DeclineTop-line has been lumpy with a slight decline in 2025 and only modest TTM growth. Reliance on large, one-off equipment orders and hospital capex cycles makes revenue timing unpredictable, complicating capacity planning and multi-period forecasting.
Inconsistent Cash Conversion / FCF VolatilityAlthough FCF is positive and improving, conversion of earnings to cash is uneven and below parity. Variable cash generation limits internal funding for growth initiatives, raises working capital sensitivity, and may necessitate external financing for larger strategic investments.
Modest Returns And Limited ScaleROE is positive but below prior stronger levels and the company remains small in headcount. Limited scale can constrain distribution, R&D leverage and bargaining power versus larger medical device competitors, making execution and margin expansion more challenging.
C-Rad AB Class B News
24C FAQ
What was C-Rad AB Class B’s price range in the past 12 months?
C-Rad AB Class B lowest stock price was €2.18 and its highest was €3.38 in the past 12 months.
What is C-Rad AB Class B’s market cap?
C-Rad AB Class B’s market cap is €112.80M.
When is C-Rad AB Class B’s upcoming earnings report date?
C-Rad AB Class B’s upcoming earnings report date is Oct 22, 2026 which is in 81 days.
How were C-Rad AB Class B’s earnings last quarter?
C-Rad AB Class B released its earnings results on Jul 17, 2026. The company reported €0.065 earnings per share for the quarter, beating the consensus estimate of €0.03 by €0.035.
Is C-Rad AB Class B overvalued?
According to Wall Street analysts C-Rad AB Class B’s price is currently Overvalued.
Does C-Rad AB Class B pay dividends?
C-Rad AB Class B does not currently pay dividends.
What is C-Rad AB Class B’s EPS estimate?
C-Rad AB Class B’s EPS estimate is 0.04.
How many shares outstanding does C-Rad AB Class B have?
C-Rad AB Class B has 32,904,050 shares outstanding.
What happened to C-Rad AB Class B’s price movement after its last earnings report?
C-Rad AB Class B reported an EPS of €0.065 in its last earnings report, beating expectations of €0.03. Following the earnings report the stock price went down -4.587%.
Which hedge fund is a major shareholder of C-Rad AB Class B?
Currently, no hedge funds are holding shares in DE:24C
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
C-Rad AB Class B
C-Rad AB (publ) develops, manufactures, and sells products and systems with applications in radiotherapy for the treatment of cancer in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company offers Catalyst+ HD, a patient positioning, intra-fraction motion management, and respiratory gating solution for conventional and stereotactic treatment delivery; Catalyst+, a solution for patient set up and intra-fraction breath hold reproducibility; Catalyst+ PT, a surface image guided radiation therapy solution that supports proton therapy from simulation to treatment; Catalyst+ HD Ring Gantry solution for patient positioning, real-time motion monitoring, and respiratory gating; and Sentinel 4DCT, a laser-based optical surface scanning system. It also provides Catalyst, a 4D surface guided radiation therapy (SGRT) solution; Catalyst HD, a SGRT solution on stereotactic radiation therapy for online patient tracking before and during treatment delivery; Catalyst PT, a tracking solution for particle therapy; and visual coaching solutions used for prospective and retrospective radiotherapy. In addition, the company offers cAutoVerify, an automation solution for the imaging suite and treatment room, automating patient identity validation, and accessory tracking; and cAccessory, which automates the registration and validation of treatment accessories. Further, it provides SmartPhantom RT, a device that allows automatic adjustment and alignment of fixed lasers with motorization; StaticPhantom, a set-up used to visually verify the precision of the alignment of lasers; high impact technology motorized system, a laser positioning system; HIT Single Diode; and HIT1, HIT3, and HIT5 patient positioning laser, as well as laser positioning products and solutions. Additionally, the company offers support and training services; and service contracts. C-Rad AB (publ) was incorporated in 2004 and is headquartered in Uppsala, Sweden.
Technical Analysis
Paxman AB
―
Senzime AB
―
Bactiguard Holding AB
―
Integrum AB Class B
―
Sedana Medical AB
―








